Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 29Triple Negative Breast Neoplasms 13Prostatic Neoplasms 13Ovarian Neoplasms 12Neoplasms 12Neoplasm Metastasis 9Fallopian Tube Neoplasms 6Leukemia, Myeloid, Acute 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumors 4Carcinoma, Renal Cell 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Recurrence 2Neuroectodermal Tumors, Primitive, Peripheral 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2mCRPC 1Wilms Tumor 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Metastatic Breast Cancer 1Thrombocythemia, Essential 1Solid Tumor 1Sarcoma 1

Interventions

talazoparib 1rucaparib 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ATM Gene Mutation × talazoparib × Clear all
NCT03377556 2021-06-23

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Phase 2 Completed
51 enrolled 18 charts

ATM Gene Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡